Department of Epidemiology and Biostatistics, National Institute for Health Development, Tallinn, Estonia.
Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.
Cancer Control. 2024 Jan-Dec;31:10732748241266491. doi: 10.1177/10732748241266491.
Despite the relatively low breast cancer incidence in Estonia, mortality remains high, and participation in mammography screening is below the recommended 70%. The objective of this register-based study was to evaluate incidence-based (IB) breast cancer mortality before and after the introduction of organized mammography screening in 2004.
Breast cancer deaths individually linked to breast cancer diagnosis were obtained from the Estonian Cancer Registry and used for calculating IB mortality. We compared age-specific IB mortality rates across 5-year birth cohorts and 5-year periods. Poisson regression was used to compare IB mortality for one age group invited to screening (50-63) and three age groups not invited to screening (30-49, 65-69, and 70+) during two periods before and after screening initiation (1993-2003 and 2004-2014). Joinpoint regression was used for age-standardized incidence and IB mortality trends.
Age-standardized IB mortality has been decreasing since 1997. Age-specific IB mortality for birth cohorts never exposed to screening showed a continuous increase with age, while in cohorts exposed to organized screening the mortality curve flattened or declined after the age of first invitation. Significant decreases in mortality from 1993-2003 to 2004-2014 were seen in the 30-49 (age-adjusted rate ratio 0.51, 95% CI 90.42-0.63) and 50-63 (0.65, 95% CI 0.56-0.74) age groups, while no decline was seen in the 65-69 and 70+ age groups.
The age specific IB mortality curves in birth cohorts exposed to screening and the significant mortality decline in the target age group after the initiation of the organized program suggest a beneficial effect of screening. Improved treatment without screening has not reduced mortality in older age groups. Our results support raising the upper screening age limit to 74 years.
尽管爱沙尼亚的乳腺癌发病率相对较低,但死亡率仍然很高,且参与乳房 X 光筛查的比例低于建议的 70%。本基于登记的研究旨在评估 2004 年实施有组织乳房 X 光筛查前后基于发病率的(IB)乳腺癌死亡率。
从爱沙尼亚癌症登记处获得单独链接到乳腺癌诊断的乳腺癌死亡病例,并用于计算 IB 死亡率。我们比较了 5 年出生队列和 5 年期间的特定年龄 IB 死亡率率。使用泊松回归比较筛查开始前后两个时期(1993-2003 年和 2004-2014 年)中一个被邀请参加筛查(50-63 岁)和三个未被邀请参加筛查(30-49 岁、65-69 岁和 70+岁)的年龄组的 IB 死亡率。使用 Joinpoint 回归分析年龄标准化发病率和 IB 死亡率趋势。
自 1997 年以来,年龄标准化 IB 死亡率一直在下降。从未接受过筛查的出生队列的特定年龄 IB 死亡率随年龄持续增加,而在接受有组织筛查的队列中,死亡率曲线在首次邀请年龄后趋于平坦或下降。从 1993-2003 年到 2004-2014 年,30-49 岁(年龄调整率比 0.51,95%CI 90.42-0.63)和 50-63 岁(0.65,95%CI 0.56-0.74)年龄组的死亡率显著下降,而 65-69 岁和 70+岁年龄组的死亡率没有下降。
接受筛查的出生队列的特定年龄 IB 死亡率曲线以及在有组织计划启动后目标年龄组的死亡率显著下降表明筛查具有有益的效果。没有筛查的治疗改善并没有降低老年人群的死亡率。我们的结果支持将上限筛查年龄提高到 74 岁。